Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis (NASDAQ: CRIS) announced on October 1, 2025 that its independent Compensation Committee approved inducement stock option grants to two new employees totaling 84,750 shares (the "Q4 2025 Inducement Grants").
Each option has an exercise price equal to the closing price of Curis common stock on October 1, 2025, a 10-year term, and vests over four years: 25% at first anniversary of hire and then 6.25% every three months, subject to continued service. The awards were granted outside the company's 2010 Stock Incentive Plan as inducements to accept employment.
Curis (NASDAQ: CRIS) ha annunciato il 1 ottobre 2025 che il suo Independent Compensation Committee ha approvato assegnazioni di stock option di induzione a due nuovi dipendenti per un totale di 84.750 azioni (le "Q4 2025 Inducement Grants").
Ogni opzione ha un prezzo di esercizio pari al prezzo di chiusura delle azioni ordinarie Curis al 1 ottobre 2025, un periodo di 10 anni e vesting su quattro anni: 25% al primo anniversario dell'assunzione e poi 6,25% ogni tre mesi, soggetto a proseguimento del servizio. Le assegnazioni sono state fuori dal piano di stock incentive del 2010 della società come incentivi all'assunzione.
Curis (NASDAQ: CRIS) anunció el 1 de octubre de 2025 que su Comité Independiente de Compensación aprobó otorgamientos de opciones de acciones de inducción a dos nuevos empleados por un total de 84.750 acciones (las "Concesiones de inducción del 4T 2025").
Cada opción tiene un precio de ejercicio igual al cierre de las acciones ordinarias Curis al 1 de octubre de 2025, un plazo de 10 años y se consolida durante cuatro años: 25% en el primer aniversario de la contratación y luego 6,25% cada tres meses, sujeto a la continuidad del servicio. Las asignaciones se otorgaron fuera del Plan de Incentivos de Acciones de 2010 de la empresa como incentivos para aceptar el empleo.
Curis (NASDAQ: CRIS)는 2025년 10월 1일에 독립 보상 위원회가 신규 직원 두 명에게 84,750주의 유인 주식매수선택권 부여를 승인했다고 발표했다(약칭 "2025년 4분기 유인 보상 부여").
각 옵션의 행사가격은 2025년 10월 1일의 Curis 보통주 종가와 동일하며, 만기 10년, 그리고 4년에 걸쳐 vesting 된다: 입사 1주년 시점에 25%이고 이후 매 3개월마다 6.25%로 vesting되며, 지속 근무 조건이 충족되어야 한다. 이 상여는 회사의 2010년 주식 인센티브 플랜 외부로 발급되어 채용을 유인하기 위한 것이다.
Curis (NASDAQ : CRIS) a annoncé le 1er octobre 2025 que son comité indépendant de rémunération a approuvé des attributions d'options d'achat d'actions d'induction à deux nouveaux employés pour un total de 84 750 actions (les « Indemnités d'induction du 4e trimestre 2025 »).
Chaque option a un prix d'exercice égal au cours de clôture des actions ordinaires Curis au 1er octobre 2025, une durée de 10 ans et vest sur quatre ans : 25 % au premier anniversaire de l'embauche puis 6,25 % tous les trimestres, sous réserve de la poursuite du service. Les attributions ont été accordées en dehors du plan 2010 d'incitation en actions de la société pour inciter à l'emploi.
Curis (NASDAQ: CRIS) hat am 1. Oktober 2025 bekannt gegeben, dass sein unabhängiges Vergütungsausschuss die induzierenden Aktienoptionszuweisungen an zwei neue Mitarbeiter in Höhe von 84.750 Aktien genehmigt hat (die „Q4 2025 Inducement Grants“).
Jede Option hat einen Ausübungspreis, der dem Schlusskurs der Curis-Stammaktie am 1. Oktober 2025 entspricht, eine Laufzeit von 10 Jahren und vestet über vier Jahre: 25 % beim ersten Jahrestag der Beschäftigung und dann 6,25 % alle drei Monate, vorbehaltlich der fortgesetzten Dienstleistung. Die Zuwendungen wurden außerhalb des 2010 Stock Incentive Plan des Unternehmens als Anreize zur Beschäftigung gewährt.
Curis (NASDAQ: CRIS) أعلنت في 1 أكتوبر 2025 أن اللجنة المستقلة للتعويض وافقت على منح خيارات أسهم تحفيزية لاثنين من الموظفين الجدد بإجمالي 84,750 سهماً (تسمى "منح الحوافز للربع الرابع من 2025").
كل خيار لديه سعر تنفيذ يساوي إغلاق أسهم Curis العادية في 1 أكتوبر 2025، ومدة استحقاق 10 سنوات، ويتحقّق vesting خلال أربع سنوات: 25% في الذكرى الأولى لتوظيف ثم 6.25% كل ثلاثة أشهر، رهناً باستمرار الخدمة. وقد مُنحت المنح خارج خطة الحافز على الأسهم لعام 2010 للشركة كحوافز لقبول العمل.
Curis (纳斯达克股票代码：CRIS) 于 2025年10月1日 宣布，其独立薪酬委员会已批准对两名新员工授予诱导性股票期权，总计 84,750股（以下简称“2025年第四季度诱导授予”）。
每个期权的行权价等于2025年10月1日 Curis普通股的收盘价，期限为10年，并在四年内归属：招聘后第一周年时为25%，随后每三个月归属6.25%，须持续任职。本次授予是在公司< b>2010年股票激励计划之外作为引进激励而授予。
- None.
- None.
Each of the Q4 2025 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on October 1, 2025. Each stock option has a 10 year term and vests over four years, with
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302575015.html
SOURCE Curis, Inc.
FAQ
How many shares did Curis (CRIS) grant under the October 1, 2025 inducement?
What is the exercise price for the CRIS inducement options dated October 1, 2025?
What are the term and vesting schedule for the CRIS Q4 2025 inducement grants?
Were the CRIS inducement options granted under the company's 2010 Stock Incentive Plan?
How many employees received inducement grants from Curis (CRIS) on October 1, 2025?
Do the CRIS inducement grants require continued service to vest?
